Horizon Europe Avrupa Birliği
Neutral-Atom Platform Technologies
This action aims to establish European leadership in neutral-atom quantum simulation and digital quantum computing by delivering: • Fully programmable industry-ready quan…
Horizon Europe · Avrupa Birliği
Development of predictive biomarkers of disease progression and treatment response by using AI methodologies…
Full title in the source: Development of predictive biomarkers of disease progression and treatment response by using AI methodologies for chronic non-communicable diseases
Açık
AB Ufuk Avrupa programı tarafından 6 hibe bekleniyor; proje başına €6 milyon – €8 milyon; toplam bütçe €44,2 milyon. Başvurular 17 Şubat 2027 tarihinde kapanıyor (AB çağrıları genellikle Brüksel saatiyle 17:00’de kapanır). AB üye ülkelerindeki ve Türkiye gibi ortak ülkelerdeki kuruluşlar genellikle katılabilir; konu koşulları belirleyicidir.
- Son başvuru
- 17 Şubat 2027 (94 gün kaldı)
- Hibe tutarı
- Proje başına €6 milyon – €8 milyon
- Toplam bütçe
- €44,2 milyon
- Destek oranı
- Uygun maliyetlerin %100’ü Bu program için standart kural; çağrı farklı olabilir.
- Toplam bütçe
- €44,2 milyon
- Beklenen hibe sayısı
- 6
- Faaliyet türü
- HORIZON Research and Innovation Actions · HORIZON Action Grant Budget-Based
- Olası başvuru sahipleri
- Şirketler, KOBİ’ler / girişimler, Kâr amacı gütmeyenler, Üniversiteler ve araştırma, Kamu kurumları Kaynak kategorilerinden veya program kurallarından; uygunluğa çağrı karar verir.
- Fon sağlayıcı
- Horizon Europe (HORIZON)
- Referans
- HORIZON-HLTH-2027-02-TOOL-01-two-stage
- Çağrı
- HORIZON-HLTH-2027-02-two-stage
- Son kontrol
- 14 Kasım 2026
Resmi açıklamalar fon sağlayıcının dilindedir (çoğunlukla İngilizce); bu sayfadaki özet ve temel bilgiler Türkçedir.
Beklenen sonuçlar
This topic aims at supporting activities that are enabling or contributing to one or several expected impacts of destination “Developing and using new tools, technologies and digital solutions for a healthy society”. To that end, proposals under this topic should aim to deliver results that are directed at, tailored towards and contributing to all the following expected outcomes:
• Clinical researchers and developers have access to novel predictive biomarkers to guide a more accurate assessment of disease progression and treatment response and tackle the unmet clinical needs of non-communicable chronic diseases.
• Clinicians and healthcare professionals use clinically validated predictive biomarkers for implementing more effective clinical research and personalised medicine with better health outcomes in chronic non-communicable diseases.
• Key stakeholders have access to trustworthy Artificial Intelligence (AI) tools to guide the development of multimodal predictive biomarkers of higher accuracy and clinical value when compared to the established practice.
Tam metni oku
• The citizens benefit of better health outcomes thanks to improved clinical guidelines and the implementation of effective biomarker-guided clinical research and personalised healthcare.
Kapsam
Biomarkers [1] are invaluable tools for improving patient outcomes, guiding treatment decisions, accelerating personalised medicine, more effective clinical research and the development of better medicines.
However, despite the scientific discoveries of many clinically relevant biomarkers, estimated on the scale of tens of thousands, only a few biomarkers have been implemented in clinical practice. The traditional ‘one biomarker’ paradigm is insufficient for addressing the unmet clinical needs of chronic, progressive and multifactorial diseases, due to the complexity of the clinical phenotypes characterised by broad inter-and intra-patient heterogeneity. The established biomarkers have limitations in their use as prognostic and predictive indicators, for the assessment of the disease progression and the choices of the optimal therapeutic interventions tailored to the patients’ characteristics.
Tam metni oku
Therefore, the topic focuses on the clinical development of predictive biomarkers of disease progression and treatment response for chronic non-communicable diseases (excluding cancer) by using established AI methodologies able to combine data of clinically used and candidate biomarkers, with available data from relevant clinical studies, longitudinal and Real-World Data (RWD) [2] . This topic is expected to support collaborative projects paving the way for future innovations in personalised medicine and enabling more timely and effective therapeutic interventions.
The proposals should address all the following research and innovation activities:
• Set-up a multidisciplinary collaboration to map and evaluate the available information and data on biomarkers currently used in the clinical setting, candidate biomarkers from past and ongoing clinical studies, which are scientifically proven as clinically relevant to the disease progression and treatment response for the chronic non-communicable diseases under study. This should include stratification by biological sex, and where feasible, integration of gender-related variables and sociodemographic determinants that may modulate disease trajectories or treatment efficacy.
• Adapt and apply of established AI methods rather than developing novel ones from scratch, to deliver novel predictive biomarkers of disease progression and treatment response, by integrating data of currently used and candidate biomarkers, with suitable data from available longitudinal and other relevant clinical studies, including RWD, as necessary. To guarantee a solid and fast optimisation and training of the AI tools, the applicants should provide information in their proposal that the appropriate high-quality clinical data are readily available, and when necessary generate small-scale new data for the AI optimisation needs. The biomarkers under study should be multimodal, covering for instance molecular, cellular, physiological, imaging, behavioural and digital markers, and/or their combinations. The applicants should justify why the…
Kimler başvurabilir
Consortium of at least 3 independent legal entities from 3 different EU Member States or associated countries, at least one in a Member State (Horizon Europe standard rule).
Başvuru sahibi kategorileri yalnızca bir başlangıç noktasıdır. Uygunluğa resmi çağrı karar verir.
Konular
Biomarkers Chronic diseases Clinical research Clinical trials Personalised medicine Software validation Artificial intelligence Clinical validation In-silico Non-communicable diseases Predictive Biomarkers clinical research
Zamanlama
Two-stage call. Next deadline 2027-02-17; later stage/cut-off 2027-09-16. The portal states the exact cut-off time (EU calls usually close at 17:00 Brussels time).
Nasıl başvurulur
- Portaldaki konunun tamamını okuyun: beklenen sonuçlar, kapsam, faaliyet türü ve ülke veya konsorsiyum kısıtlamaları dahil uygunluk koşulları.
- Kuruluşunuzu AB Funding & Tenders Portalına kaydederek her ortak için bir PIC numarası alın.
- İşbirliğine dayalı araştırma ve yenilik projeleri genellikle üç farklı AB üye ülkesi veya ortak ülkeden en az üç bağımsız ortak gerektirir (Türkiye Ufuk Avrupa’ya ortak ülkedir). Bu konudaki kuralı doğrulayın.
- Bölüm A’yı (portalda doldurulan idari formlar ve bütçe) ve Bölüm B’yi (bu faaliyet türü için resmi şablondaki teknik açıklama) hazırlayın.
- Son başvuru günü kapanış saatinden önce portal üzerinden gönderin. Geç başvurular kabul edilmez.
From the call text
- Who can apply
- Not stated in the call text we hold — check the official page
- Company stage
- Not stated in the call text we hold — check the official page
- Single applicant or consortium
- Read the topic conditions on the EU Funding & Tenders Portal for eligible countries, consortium requirements, budget and the application route.
- Where applicants must be based
- Read the topic conditions on the EU Funding & Tenders Portal for eligible countries, consortium requirements, budget and the application route.
- Where to apply
- Read the topic conditions on the EU Funding & Tenders Portal for eligible countries, consortium requirements, budget and the application route.
Resmi kaynaklar
Bu sayfadaki bilgiler resmi kaynaktan alınmıştır ve en son 14 Kasım 2026 tarihinde kontrol edilmiştir. Sonraki değişiklikler dahil, fon sağlayıcının kendi belgeleri her zaman önceliklidir.
Horizon Europe: diğer çağrılar
Horizon Europe Avrupa Birliği
Next-Generation QKD Systems
This action will strengthen Europe's strategic autonomy in quantum-secure communications by advancing core QKD technologies and integration capabilities. Expected results…
Horizon Europe Avrupa Birliği
Quantum Experimental Pilot Lines for Quantum Technologies
This action will strengthen Europe's leadership and strategic autonomy in quantum technologies by advancing experimental pilot line capacities as a vital stepping stone t…
Horizon Europe Avrupa Birliği
Quantum-Testing Infrastructure for Quantum Technologies
This action will establish a pan-European open-access testing and experimentation infrastructure for quantum technologies, enabling systematic validation and certificatio…
Horizon Europe Avrupa Birliği
Superconducting Platform Technologies
This action will consolidate Europe’s position in superconducting quantum computing through: • Establishment of a full-stack superconducting quantum computer aiming at 1.…